Literature DB >> 22244550

[Hemoglobin: simply a laboratory value or a powerful predictor of risk in patients with acute coronary syndrome?].

Muriel Ferreira1, Natália António, Francisco Gonçalves, Pedro Monteiro, Lino Gonçalves, Mário Freitas, Luís Augusto Providência.   

Abstract

INTRODUCTION: Anemia has been shown to be associated with a worse prognosis, especially higher mortality in various pathological conditions. However, few studies have specifically examined its impact in acute coronary syndrome (ACS) patients. The purpose of our study was to assess the association between different quartiles of hemoglobin on admission and short- and long-term prognosis in patients with ACS.
METHODS: We performed a retrospective analysis of 1303 consecutive ACS patients admitted to a coronary care unit and analyzed the association between baseline hemoglobin and morbidity and mortality, in-hospital and at 12-month follow-up. The population was divided into groups according to quartiles of hemoglobin concentration (Hb): Q1: <10.8g/dl; Q2: 10.8-12.2g/dl; Q3: 12.3-13.2g/dl; Q4: ≥13.3g/dl. Logistic regression analysis was used to identify independent predictors of short- and long-term mortality.
RESULTS: Hypertension and diabetes mellitus were more common in the lower Hb quartiles, while the prevalence of smoking and physical inactivity increased with higher Hb. A higher proportion of patients in the lower quartiles had congestive heart failure, peripheral artery disease and previous stroke or transient ischemic attack. Anemic patients tended to be older, with worse renal function and left ventricular systolic function. Patients in Q1 had significantly higher levels of troponin I and blood glucose on admission. Anemic patients showed significantly higher in-hospital mortality (Q1: 9.8%; Q2: 6.3%; Q3: 4.1%; Q4: 3.6%, p<0.001), longer hospital stay (Q1: 6.1±4.4; Q2: 5.2±3.0; Q3: 4.9±2.7; Q4 4.3±2.1 days, p<0.001) and higher 1-year mortality (Q1: 23.6%; Q2: 11.6%; Q3: 10.6%; Q4: 5.5%, p<0.001). In multivariate analysis, the only independent predictor of in-hospital mortality was Killip class >1 at admission. The independent predictors of long-term mortality were age ≥69.5 years, Killip class >1 at admission, diabetes mellitus, ST-segment depression on admission ECG and Hb <10.8g/dl. DISCUSSION AND
CONCLUSIONS: Low baseline hemoglobin is associated with more comorbidities and can accurately predict 1-year mortality after an acute coronary syndrome.
Copyright © 2011 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244550     DOI: 10.1016/j.repc.2011.12.013

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  4 in total

1.  A Prospective Study on Prevalence and Causes of Anaemia in Patients with Acute Coronary Syndrome.

Authors:  Penta Bhavanadhar; Vangipuram Rangacharyulu Srinivasan; Sai Satish Oruganti; Krishna Prasad Adiraju
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Prevalence of Conventional Risk Factors and Evaluation of Baseline Indices Among Young and Elderly Patients with Coronary Artery Disease.

Authors:  Arsalan Majeed Adam; Aiman Rehan; Nageen Waseem; Unzela Iqbal; Hira Saleem; Muhammad Armughan Ali; Ali Tariq Shaikh; Ansab Godil
Journal:  J Clin Diagn Res       Date:  2017-07-01

3.  Prognostic score for acute coronary syndrome in a private terciary hospital.

Authors:  Edson Renato Romano; Ieda Maria Liguori; Jorge Alcantara Farran; Rosa Maria Pimentel do Egito; Marcelo Luz Pereira Romano; Vinícius Avellar Werneck; Marco Antonio Oliveira Barbosa; Enilton Sergio Tabosa do Egito; Alexandre Biasi Cavalcanti; Leopoldo Soares Piegas
Journal:  Arq Bras Cardiol       Date:  2014-02-10       Impact factor: 2.000

4.  Hb Levels and Sex Differences in Relation to Short-Term Outcomes in Patients With Acute Myocardial Infarction.

Authors:  Junyu Pei; Xiaopu Wang; Pengfei Chen; Keyang Zheng; Xinqun Hu
Journal:  Front Cardiovasc Med       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.